- Patient outcomes were defined by protocol (n=107) or for-cause (n=44) kidney biopsy.
- Median time to biopsy and Tutivia risk score was 57 days, and a high risk score predicting acute rejection as early as 6 days post-transplant.
80% of clinically indicated biopsies were performed within the first sixty days.
- 69% of these had acute rejection by histopathology.
- 83% of early biopsies with pathologic acute rejection had a high Tutivia risk score.
Clarava™ is the first pre-transplant prognostic test to assess a patient's immune phenotype for the probable risk of early kidney graft rejection. The validation study represents a significant demonstration of Clarava™ as a predictive test capable of informing a clear, actionable response from clinicians. Verici Dx is on track to make Clarava™ available by the end of 2023.
Tutivia™ is a blood-based transcriptomic signature that utilizes RNA expression values of select genes, with a proprietary algorithm, to correlate an acute rejection risk score with rejection phenotype, based upon kidney biopsy histopathology, using BANFF 2019 criteria. For more information about the Tutivia™ validation study go to vericidx.com, then click on the product section at the top, then click on Tutivia™.